Drug delivery interfaces in the 21st century: From science fiction ideas to viable technologies

Molecular Pharmaceutics

Volumn 10, Issue 10, 2013, Pages 3531-3543

  Chertok, Beata ^a,b   Webber, Matthew J ^b,c   Succi, Marc D ^b,d,e   Langer, Robert ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Controlled release implants; Drug carriers; Drug delivery; Nanotechnology; Pharmacokinetics; Physiological barriers; Translational medicine

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BIOMATERIAL; BLEOMYCIN; CARMUSTINE; DOXORUBICIN; DRUG CARRIER; GLUCOSE; GOLD NANOPARTICLE; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; LIPOPROTEIN; LIPOSOME; NANOPARTICLE; PARATHYROID HORMONE[1-34]; PERFLUORO COMPOUND; PIG INSULIN; PLASMA PROTEIN; PLATINUM; POLYGLACTIN; POLYMER; PROTEOME; RECOMBINANT PARATHYROID HORMONE; SILK FIBROIN; TITANIUM; TRANSCRIPTOME; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ANTICOAGULANT THERAPY; BIOCOMPATIBILITY; BIODEGRADABILITY; BIONICS; BONE DENSITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COMPUTER AIDED DESIGN; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER SYSTEM; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE IMPLANT; CYBORG; DRUG BLOOD LEVEL; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANT; DRUG IMPLANTATION; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG TRANSPORT; ELECTRIC CURRENT; ELECTRODE; ELECTRONICS; EPIGENETICS; ERYTHROCYTE MEMBRANE; FRACTURE; GLIOMA; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN GENOME; HYDROGEL; INSULIN TREATMENT; KAPOSI SARCOMA; KINETICS; LAB ON A CHIP; LOW DRUG DOSE; MACHINE LEARNING; MACROMOLECULE; MAGNETIC FIELD; MATERIALS; METABOLOME; MICELLE; MICROVASCULATURE; NANOTECHNOLOGY; NEOVASCULARIZATION (PATHOLOGY); NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATIENT COMPLIANCE; PHAGOCYTOSIS; PHARMACEUTICAL ENGINEERING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SCANNING ELECTRON MICROSCOPY; SCIENCE; SOLID TUMOR; TARGET CELL; TECHNOLOGY; THROMBOSIS; ULTRASOUND; UNSPECIFIED SIDE EFFECT;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84888390732     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp4003283     Document Type: Review

References (118)

1. Wagner, J. G. History of pharmacokinetics. Pharmacol. Ther. 1981, 12 (3), 537-562.
2. De Jong, S. E.; Wijans, M. The influence of divided doses of drugs on the duration of effect and integral of effect. Acta Physiol. Pharmacol. Neerl. 1950, 1, 237-258.
3. Van Gemert, A. G. M.; Duyff, J. W. Optimal dosage of drugs. Acta Physiol. Pharmacol. Neerl. 1950, No. 1, 256-278.
4. Rose, S.; Nelson, J. F. A continuous long-term injector. Aust. J. Exp. Biol. Med. Sci. 1955, 33 (4), 415-419.
5. Clynes, M. E.; Kline, N. S. Cyborgs and Space. Astronautics 1960, 26-27.
6. Panchagnula, R.; Thomas, N. S. Biopharmaceutics and pharmacokinetics in drug research. Int. J. Pharm. 2000, 201 (2), 131-150.
7. American Cancer Society. Cancer Facts and Figures 2013; American Cancer Society: Atlanta, GA, 2013.
8. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Background Information Regarding Accelerated Approval of DOXIL® in AIDS-Related Kaposi's Sarcoma. Oncologic Drugs Advisory Committee (ODAC) Meeting; 2005.
9. Speth, P. A.; van Hoesel, Q. G.; Haanen, C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 1988, 15 (1), 15-31.
10. McEvoy, G. K. AHFS Drug Information: Doxorubicin Hydrochloride; American Society of Health-System Pharmacists: 2013.
11. Westphal, M.; Hilt, D. C.; Bortey, E.; Delavault, P.; Olivares, R.; Warnke, P. C.; Whittle, I. R.; Jaaskelainen, J.; Ram, Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 2003, 5 (2), 79-88.
12. Perry, J.; Chambers, A.; Spithoff, K.; Laperriere, N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr. Oncol. (Toronto, Ont.) 2007, 14 (5), 189-194.
13. Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet: National estimates and general information on diabetes and prediabetes in the United States; Department of Health and Human Services, Centers for Disease Control and Prevention: Atlanta, GA, 2011.
14. Duckworth, W. C.; Bennett, R. G.; Hamel, F. G. Insulin Degradation: Progress and Potential. Endocr. Rev. 1998, 19 (5), 608-624.
15. Muggeo, M.; Zoppini, G.; Bonora, E.; Brun, E.; Bonadonna, R. C.; Moghetti, P.; Verlato, G. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000, 23 (1), 45-50.
16. Golan, D. E.; Tashjian, A. H., Jr.; Armstrong, E. J.; Armstrong, A. W. Principles of Pharmacology, 2nd ed.; Lippincott Williams & Wilkins: Baltimore, MD, 2008.
17. Reginster, J. Y.; Burlet, N. Osteoporosis: a still increasing prevalence. Bone 2006, 38 (2 Suppl. 1), S4-9.
18. Lindsay, R.; Nieves, J.; Formica, C.; Henneman, E.; Woelfert, L.; Shen, V.; Dempster, D.; Cosman, F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350 (9077), 550-555.
19. Greenspan, S. L.; Bone, H. G.; Ettinger, M. P.; Hanley, D. A.; Lindsay, R.; Zanchetta, J. R.; Blosch, C. M.; Mathisen, A. L.; Morris, S. A.; Marriott, T. B. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 2007, 146, 326-339.
20. Hock, J. M.; Gera, I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J. Bone Miner. Res. 1992, 7 (1), 65-72.
21. Pleiner-Duxneuner, J.; Zwettler, E.; Paschalis, E.; Roschger, P.; Nell-Duxneuner, V.; Klaushofer, K. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif. Tissue Int. 2009, 84 (3), 159-170.
22. Rubin, M. R.; Bilezikian, J. P. New anabolic therapies in osteoporosis. Current Opinion Rheumatol. 2002, 14 (4), 433-440.
23. Aslan, D.; Andersen, M. D.; Gede, L. B.; de Franca, T. K.; Jorgensen, S. R.; Schwarz, P.; Jorgensen, N. R. Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand. J. Clin. Lab. Invest. 2012, 72 (1), 14-22.
24. Han, S. L.; Wan, S. L. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int. J. Clin. Pract. 2012, 66 (2), 199-209.
25. Gold, D. T.; Weinstein, D. L.; Pohl, G.; Krohn, K. D.; Chen, Y.; Meadows, E. S. Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational Study. J. Osteoporosis 2011, 2011, 314970.
26. Marhefka, J. N.; Velankar, S. S.; Chapman, T. M.; Kameneva, M. V. Mechanical degradation of drag reducing polymers in suspensions of blood cells and rigid particles. Biorheology 2008, 45 (5), 599-609.
27. Merkel, T. J.; Jones, S. W.; Herlihy, K. P.; Kersey, F. R.; Shields, A. R.; Napier, M.; Luft, J. C.; Wu, H.; Zamboni, W. C.; Wang, A. Z.; Bear, J. E.; DeSimone, J. M. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (2), 586-591.
28. Stein, P. D.; Sabbah, H. N. Turbulent blood flow in the ascending aorta of humans with normal and diseased aortic valves. Circ. Res. 1976, 39 (1), 58-65.
29. Ku, D. N. Blood flow in arteries. Annu. Rev. Fluid Mech. 1997, 29, 399-434.
30. Gualtieri, P.; Picano, F.; Sardina, G.; Casciola, C. M. Clustering and turbulence modulation in particle laden shear flows. J. Phys.: Conf. Ser. 2011, 333, 1-15.
31. Lin, J.; Liu, S.; Chan, T. Nanoparticle migration in a fully developed turbulent pipe flow considering the particle coagulation. Chin. J. Chem. Eng. 2012, 20 (4), 679-685.
32. Korin, N.; Kanapathipillai, M.; Matthews, B. D.; Crescente, M.; Brill, A.; Mammoto, T.; Ghosh, K.; Jurek, S.; Bencherif, S. A.; Bhatta, D.; Coskun, A. U.; Feldman, C. L.; Wagner, D. D.; Ingber, D. E. Shearactivated nanotherapeutics for drug targeting to obstructed blood vessels. Science 2012, 337 (6095), 738-742.
33. Williams, K. J.; Phillips, M. C.; Rodrigueza, W. V. Structural and metabolic consequences of liposome-lipoprotein interactions. Adv. Drug Delivery Rev. 1998, 32 (1-2), 31-43.
34. Moghimi, S. M.; Hunter, A. C.; Andresen, T. L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 481-503.
35. Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Delivery Rev. 2009, 61 (6), 428-437.
36. Rodriguez, P. L.; Harada, T.; Christian, D. A.; Pantano, D. A.; Tsai, R. K.; Discher, D. E. Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339 (6122), 971-975.
37. Choi, H. S.; Liu, W.; Misra, P.; Tanaka, E.; Zimmer, J. P.; Itty Ipe, B.; Bawendi, M. G.; Frangioni, J. V. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25 (10), 1165-1170.
38. Protzer, U.; Maini, M. K.; Knolle, P. A. Living in the liver: hepatic infections. Nat. Rev. Immunol. 2012, 12 (3), 201-213.
39. Mebius, R. E.; Kraal, G. Structure and function of the spleen. Nat. Rev. Immunol. 2005, 5 (8), 606-616.
40. Moghimi, S. M.; Porter, C. J.; Muir, I. S.; Illum, L.; Davis, S. S. Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating. Biochem. Biophys. Res. Commun. 1991, 177 (2), 861-6.
41. Menna, P.; Salvatorelli, E.; Gianni, L.; Minotti, G. Anthracycline cardiotoxicity. Top. Curr. Chem. 2008, 283, 21-44.
42. Lukyanenko, V. Delivery of nano-objects to functional subdomains of healthy and failing cardiac myocytes. Nanomedicine (London) 2007, 2 (6), 831-486.
43. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (8), 4607-4612.
44. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207.
45. Wang, J.; Byrne, J. D.; Napier, M. E.; DeSimone, J. M. More effective nanomedicines through particle design. Small 2011, 7 (14), 1919-1931.
46. McLennan, D. N.; Porter, C. J. H.; Charman, S. A. Subcutaneous drug delivery and the role of the lymphatics. Drug Discovery Today: Technol. 2005, 2 (1), 89-96.
47. Swartz, M. A. The physiology of the lymphatic system. Adv. Drug Delivery Rev. 2001, 50 (1-2), 3-20.
48. Amidon, G. L.; Lee, H. J. Absorption of peptide and peptidomimetic drugs. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 321-341.
49. Rojanasakul, Y.; Wang, L. Y.; Bhat, M.; Glover, D. D.; Malanga, C. J.; Ma, J. K. The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm. Res. 1992, 9 (8), 1029-1034.
50. Owens, D. R.; Jones, M. K.; Hayes, T. M.; Heding, L. G.; Alberti, K. G.; Home, P. D.; Burrin, J. M. Comparative study of subcutaneous, intramuscular, and intravenous administration of human insulin. Lancet 1981, 2 (8238), 118-122.
51. Lauritzen, T.; Pramming, S.; Deckert, T.; Binder, C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983, 24 (5), 326-329.
52. Williams, D. F. On the mechanisms of biocompatibility. Biomaterials 2008, 29 (20), 2941-2953.
53. Liu, Y.; Mounkes, L. C.; Liggitt, H. D.; Brown, C. S.; Solodin, I.; Heath, T. D.; Debs, R. J. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 1997, 15 (2), 167-173.
54. Muller, R. H.; Mader, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50 (1), 161-177.
55. Wattendorf, U.; Merkle, H. P. PEGylation as a tool for the biomedical engineering of surface modified microparticles. J. Pharm. Sci. 2008, 97 (11), 4655-4669.
56. Farokhzad, O. C.; Karp, J. M.; Langer, R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Delivery 2006, 3 (3), 311-324.
57. Geng, Y.; Dalhaimer, P.; Cai, S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D. E. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2007, 2 (4), 249-255.
58. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Delivery Rev. 2003, 55 (3), 329-347.
59. Udhrain, A.; Skubitz, K. M.; Northfelt, D. W. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int. J. Nanomed. 2007, 2 (3), 345-352.
60. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54 (4), 987-992.
61. Gabizon, A. F.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 2003, 42 (5), 419-436.
62. Northfelt, D. W.; Martin, F. J.; Working, P.; Volberding, P. A.; Russell, J.; Newman, M.; Amantea, M. A.; Kaplan, L. D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 1996, 36 (1), 55-63.
63. O'Brien, M. E.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D. G.; Tomczak, P.; Ackland, S. P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 2004, 15 (3), 440-449.
64. Pissuwan, D.; Valenzuela, S. M.; Cortie, M. B. Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends Biotechnol. 2006, 24 (2), 62-67.
65. O'Neal, D. P.; Hirsch, L. R.; Halas, N. J.; Payne, J. D.; West, J. L. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004, 209 (2), 171-176.
66. Chertok, B.; David, A. E.; Yang, V. C. Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials 2011, 32 (26), 6245-6253.
67. Dromi, S.; Frenkel, V.; Luk, A.; Traughber, B.; Angstadt, M.; Bur, M.; Poff, J.; Xie, J.; Libutti, S. K.; Li, K. C.; Wood, B. J. Pulsedhigh intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin. Cancer Res. 2007, 13 (9), 2722-2727.
68. Frenkel, V.; Etherington, A.; Greene, M.; Quijano, J.; Xie, J.; Hunter, F.; Dromi, S.; Li, K. C. Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure. Acad. Radiol. 2006, 13 (4), 469-479.
69. Stone, M. J.; Frenkel, V.; Dromi, S.; Thomas, P.; Lewis, R. P.; Li, K. C.; Horne, M., 3rd; Wood, B. J. Pulsed-high intensity focused ultrasound enhanced tPA mediated thrombolysis in a novel in vivo clot model, a pilot study. Thromb. Res. 2007, 121 (2), 193-202.
70. Folkman, J.; Long, D. M., Jr.; Rosenbaum, R. Silicone rubber: a new diffusion property useful for general anesthesia. Science 1966, 154 (3745), 148-149.
71. Folkman, J.; Long, D. M. The Use of Silicone Rubber as a Carrier for Prolonged Drug Therapy. J. Surg. Res. 1964, 4, 139-142.
72. Langer, R.; Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976, 263 (5580), 797-800.
73. Langer, R.; Tirrell, D. A. Designing materials for biology and medicine. Nature 2004, 428 (6982), 487-492.
74. Anderson, D. G.; Burdick, J. A.; Langer, R. Materials science. Smart biomaterials. Science 2004, 305 (5692), 1923-1924.
75. Ulijn, R. V. Enzyme-responsive materials: a new class of smart biomaterials. J. Mater. Chem. 2006, 16, 2217-2225.
76. Langer, R. Polymer implants for drug delivery in the brain. J. Controlled Release 1991, 16, 53-60.
77. Attenello, F. J.; Mukherjee, D.; Datoo, G.; McGirt, M. J.; Bohan, E.; Weingart, J. D.; Olivi, A.; Quinones-Hinojosa, A.; Brem, H. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann. Surg. Oncol. 2008, 15 (10), 2887-2893.
78. Westphal, M.; Ram, Z.; Riddle, V.; Hilt, D.; Bortey, E. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir. (Wien) 2006, 148 (3), 269-275, discussion. 275.
79. Richards Grayson, A. C.; Choi, I. S.; Tyler, B. M.; Wang, P. P.; Brem, H.; Cima, M. J.; Langer, R. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat. Mater. 2003, 2 (11), 767-772.
80. Prescott, J. H.; Lipka, S.; Baldwin, S.; Sheppard, N. F., Jr.; Maloney, J. M.; Coppeta, J.; Yomtov, B.; Staples, M. A.; Santini, J. T., Jr. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat. Biotechnol. 2006, 24 (4), 437-438.
81. Maloney, J. M.; Uhland, S. A.; Polito, B. F.; Sheppard, N. F., Jr.; Pelta, C. M.; Santini, J. T., Jr. Electrothermally activated microchips for implantable drug delivery and biosensing. J. Controlled Release 2005, 109 (1-3), 244-255.
82. Bratlie, K. M.; York, R. L.; Invernale, M. A.; Langer, R.; Anderson, D. G. Materials for diabetes therapeutics. Adv. Healthcare Mater. 2012, 1 (3), 267-284.
83. Brown, L.; Munoz, C.; Siemer, L.; Edelman, E.; Langer, R. Controlled release of insulin from polymer matrices. Control of diabetes in rats. Diabetes 1986, 35 (6), 692-697.
84. Brown, L. R.; Edelman, E. R.; Fischel-Ghodsian, F.; Langer, R. Characterization of glucose-mediated insulin release from implantable polymers. J. Pharm. Sci. 1996, 85 (12), 1341-1345.
85. Kost, J.; Langer, R. Responsive polymer systems for controlled delivery of therapeutics. Trends Biotechnol. 1992, 10 (4), 127-131.
86. Gu, Z.; Aimetti, A. A.; Wang, Q.; Dang, T. T.; Zhang, Y.; Veiseh, O.; Cheng, H.; Langer, R. S.; Anderson, D. G. Injectable Nano-Network for Glucose-Mediated Insulin Delivery. ACS Nano 2013, 7 (5), 4194-4201.
87. Rolland, J. P.; Maynor, B. W.; Euliss, L. E.; Exner, A. E.; Denison, G. M.; DeSimone, J. M. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 2005, 127 (28), 10096-10100.
88. Kelly, J. Y.; DeSimone, J. M. Shape-specific, monodisperse nanomolding of protein particles. J. Am. Chem. Soc. 2008, 130 (16), 5438-5439.
89. Schmidt, V.; Kuna, L.; Satzinger, V.; Jakopic, G.; Leising, G. Two-photon 3D lithography: A Versatile Fabrication Method for Complex 3D Shapes and Optical Interconnects within the Scope of Innovative Industrial Applications. J. Laser Micro/Nanoeng. 2007, 2 (3), 170-177.
90. Lee, K.; Kim, R.; Yang, D.; Park, S. Advances in 3D nano/microfabrication using two-photon initiated polymerization. Prog. Polym. Sci. 2008, 33 (6), 631-681.
91. Yang, D.; Park, S.; Lim, T.; Kong, H.; Yi, S.; Yang, H.; Lee, K. Ultraprecise microreproduction of a three-dimensional artistic sculpture by multipath scanning method in two-photon photopolymerization. Appl. Phys. Lett. 2007, 90 (1), 013113.
92. Hu, C. M.; Zhang, L.; Aryal, S.; Cheung, C.; Fang, R. H.; Zhang, L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (27), 10980-10985.
93. Schneider, G.; Guttmann, P.; Heim, S.; Rehbein, S.; Mueller, F.; Nagashima, K.; Heymann, J.; Muller, W.; McNally, J. Threedimensional cellular ultrastructure resolved by X-ray microscopy. Nat. Methods 2010, 7 (12), 985-U116.
94. Leis, A.; Rockel, B.; Andrees, L.; Baumeister, W. Visualizing cells at the nanoscale. Trends Biochem. Sci. 2009, 34 (2), 60-70.
95. Hohmann-Marriott, M.; Sousa, A.; Azari, A.; Glushakova, S.; Zhang, G.; Zimmerberg, J.; Leapman, R. Nanoscale 3D cellular imaging by axial scanning transmission electron tomography. Nat. Methods 2009, 6 (10), 729-732.
96. McKillop, A. M.; Flatt, P. R. Emerging applications of metabolomic and genomic profiling in diabetic clinical medicine. Diabetes Care 2011, 34 (12), 2624-2630.
97. Manolio, T. A.; Collins, F. S. The HapMap and genome-wide association studies in diagnosis and therapy. Annu. Rev. Med. 2009, 60, 443-456.
98. Honda, K.; Ono, M.; Shitashige, M.; Masuda, M.; Kamita, M.; Miura, N.; Yamada, T. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. Jpn. J. Clin. Oncol. 2013, 43 (2), 103-109.
99. Newcomb, C. J.; Moyer, T. J.; Lee, S. S.; Stupp, S. I. Advances in cryogenic transmission electron microscopy for the characterization of dynamic self-assembling nanostructures. Curr. Opin. Colloid Interface Sci. 2012, 17 (6), 350-359.
100. Ricotti, L.; Assaf, T.; Dario, P.; Menciassi, A. Wearable and implantable pancreas substitutes. J. Artif. Organs 2013, 16 (1), 9-22.
101. Simon, D.; Kurup, S.; Larsson, K.; Hori, R.; Tybrandt, K.; Goiny, M.; Jager, E.; Berggren, M.; Canlon, B.; Richter-Dahlfors, A. Organic electronics for precise delivery of neurotransmitters to modulate mammalian sensory function. Nat. Mater. 2009, 8 (9), 742-746.
102. De Micheli, G. An outlook on design technologies for future integrated systems. IEEE Trans. Comput.-Aided Des. Integr. Circuits Syst. 2009, 28 (6), 777-790.
103. Disney, D.; Shen, Z. Review of Silicon Power Semiconductor Technologies for Power Supply on Chip and Power Supply in Package Applications. IEEE Trans. Power Electron. 2013, 28 (9), 4168-4181.
104. Farra, R.; Sheppard, N.; McCabe, L.; Neer, R.; Anderson, J.; Santini, J.; Cima, M.; Langer, R. First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip. Sci. Transl. Med. 2012, 4 (122), 122ra21.
105. Irimia-Vladu, M.; Glowacki, E.; Voss, G.; Bauer, S.; Sariciftci, N. Green and biodegradable electronics. Mater. Today 2012, 15 (7-8), 340-346.
106. Muskovich, M.; Bettinger, C. Biomaterials-Based Electronics: Polymers and Interfaces for Biology and Medicine. Adv. Healthcare Mater. 2012, 1 (3), 248-266.
107. Kim, D.; Viventi, J.; Amsden, J.; Xiao, J.; Vigeland, L.; Kim, Y.; Blanco, J.; Panilaitis, B.; Frechette, E.; Contreras, D.; Kaplan, D.; Omenetto, F.; Huang, Y.; Hwang, K.; Zakin, M.; Litt, B.; Rogers, J. Dissolvable films of silk fibroin for ultrathin conformal bio-integrated electronics. Nat. Mater. 2010, 9 (6), 511-517.
108. Stadler, P.; Oppelt, K.; Singh, T.; Grote, J.; Schwodiauer, R.; Bauer, S.; Piglmayer-Brezina, H.; Bauerle, D.; Sariciftci, N. Organic field-effect transistors and memory elements using deoxyribonucleic acid (DNA) gate dielectric. Org. Electron. 2007, 8 (6), 648-654.
109. Zhong, C.; Deng, Y.; Roudsari, A.; Kapetanovic, A.; Anantram, M.; Rolandi, M. A polysaccharide bioprotonic field-effect transistor. Nat. Commun. 2011, 2, DOI: 10.1038/ncomms1489.
110. Brown, B.; Badylak, S. Expanded applications, shifting paradigms and an improved understanding of host-biomaterial interactions. Acta Biomater. 2013, 9 (2), 4948-4955.
111. Anderson, J.; Rodriguez, A.; Chang, D. Foreign body reaction to biomaterials. Semin. Immunol. 2008, 20 (2), 86-100.
112. Skousen, J.; Merriam, M.; Srivannavit, O.; Perlin, G.; Wise, K.; Tresco, P. Reducing surface area while maintaining implant penetrating profile lowers the brain foreign body response to chronically implanted planar silicon microelectrode arrays. Prog. Brain Res. 2011, 194, 167-180.
113. Sanders, J.; Stiles, C.; Hayes, C. Tissue response to singlepolymer fibers of varying diameters: Evaluation of fibrous encapsulation and macrophage density. J. Biomed. Mater. Res. 2000, 52 (1), 231-237.
114. Casadio, M.; Ranganathan, R.; Mussa-Ivaldi, F. A. The bodymachine interface: a new perspective on an old theme. J. Motor Behav. 2012, 44 (6), 419-433.
115. Tessadori, J.; Bisio, M.; Martinoia, S.; Chiappalone, M. Modular neuronal assemblies embodied in a closed-loop environment: toward future integration of brains and machines. Front. Neural Circuits 2012, 6, 99.
116. Carmena, J. M. Advances in neuroprosthetic learning and control. PLoS Biol. 2013, 11 (5), e1001561.
117. Hovorka, R. Continuous glucose monitoring and closed-loop systems. Diabetic Med. 2006, 23 (1), 1-12.
118. Bellisle, F.; Louis-Sylvestre, J.; Demozay, F.; Blazy, D.; Le Magnen, J. Cephalic phase of insulin secretion and food stimulation in humans: a new perspective. Am. J. Physiol. 1985, 249 (6 Part 1), E639-E645.